- Home
- EYPT vs HUMA Comparison
EYPT vs HUMA Comparison
Compare EYPT & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYPT
- HUMA
- Stock Information
- Founded
- EYPT 1987
- HUMA 2004
- Country
- EYPT United States
- HUMA United States
- Employees
- EYPT N/A
- HUMA N/A
- Industry
- EYPT Biotechnology: Laboratory Analytical Instruments
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- EYPT Industrials
- HUMA Health Care
- Exchange
- EYPT Nasdaq
- HUMA Nasdaq
- Market Cap
- EYPT 594.5M
- HUMA 577.7M
- IPO Year
- EYPT 2005
- HUMA N/A
- Fundamental
- Price
- EYPT $8.12
- HUMA $3.81
- Analyst Decision
- EYPT Strong Buy
- HUMA Strong Buy
- Analyst Count
- EYPT 8
- HUMA 7
- Target Price
- EYPT $27.29
- HUMA $12.71
- AVG Volume (30 Days)
- EYPT 918.1K
- HUMA 2.6M
- Earning Date
- EYPT 11-07-2024
- HUMA 11-08-2024
- Dividend Yield
- EYPT N/A
- HUMA N/A
- EPS Growth
- EYPT N/A
- HUMA N/A
- EPS
- EYPT N/A
- HUMA N/A
- Revenue
- EYPT $45,713,000.00
- HUMA N/A
- Revenue This Year
- EYPT N/A
- HUMA N/A
- Revenue Next Year
- EYPT N/A
- HUMA $6,438.24
- P/E Ratio
- EYPT N/A
- HUMA N/A
- Revenue Growth
- EYPT 7.50
- HUMA N/A
- 52 Week Low
- EYPT $7.21
- HUMA $2.48
- 52 Week High
- EYPT $30.99
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- EYPT 41.68
- HUMA 36.01
- Support Level
- EYPT $7.21
- HUMA $3.56
- Resistance Level
- EYPT $8.21
- HUMA $4.42
- Average True Range (ATR)
- EYPT 0.49
- HUMA 0.33
- MACD
- EYPT -0.02
- HUMA -0.03
- Stochastic Oscillator
- EYPT 42.82
- HUMA 16.27
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.